Project Details
| Status | Active |
|---|---|
| Effective start/end date | 06/23/26 → 06/7/27 |
Funding
- Janssen Research and Development LLC: $6,604.00
OrigAMI-3: A Randomized, Open-label Phase 3 Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer who have
- Padhi, Parikshit (PI)
Project: Research